| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Active surveillance for squamous-cell head and neck carcinoma
|
Burki, Talha Khan
|
|
2016
|
17 |
5 |
p. e183-
1 p.
|
artikel
|
| 2 |
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|
Park, Keunchil
|
|
2016
|
17 |
5 |
p. 577-589
13 p.
|
artikel
|
| 3 |
2016 Annual Meeting of the Society of Gynecologic Oncology
|
Sklan, Alex
|
|
2016
|
17 |
5 |
p. 562-
1 p.
|
artikel
|
| 4 |
Before I kick the bucket: the whole story
|
Kirby, Tony
|
|
2016
|
17 |
5 |
p. 566-
1 p.
|
artikel
|
| 5 |
Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study
|
Bertucci, François
|
|
2016
|
17 |
5 |
p. 600-611
12 p.
|
artikel
|
| 6 |
Beyond a moonshot: insurance coverage for proton therapy
|
Shah, Anand
|
|
2016
|
17 |
5 |
p. 559-561
3 p.
|
artikel
|
| 7 |
Brexit: a European perspective
|
Tabernero, Josep
|
|
2016
|
17 |
5 |
p. 558-559
2 p.
|
artikel
|
| 8 |
CAN.recall
|
Hiew, Samantha
|
|
2016
|
17 |
5 |
p. 564-
1 p.
|
artikel
|
| 9 |
Chemoradiotherapy for grade 2 glioma improves survival
|
Baker, Holly
|
|
2016
|
17 |
5 |
p. e186-
1 p.
|
artikel
|
| 10 |
Chemotherapy benefit for paediatric neurofibromatosis type I
|
Brower, Vicki
|
|
2016
|
17 |
5 |
p. e186-
1 p.
|
artikel
|
| 11 |
Chemotherapy risks to fertility of childhood cancer survivors
|
Anderson, Richard A
|
|
2016
|
17 |
5 |
p. 540-541
2 p.
|
artikel
|
| 12 |
Correction to Lancet Oncol 2016; 17: 541
|
|
|
2016
|
17 |
5 |
p. e181-
1 p.
|
artikel
|
| 13 |
Correction to Lancet Oncol 2016; 17: 456
|
|
|
2016
|
17 |
5 |
p. e181-
1 p.
|
artikel
|
| 14 |
Correction to Lancet Oncol 2016; 17: 416
|
|
|
2016
|
17 |
5 |
p. e181-
1 p.
|
artikel
|
| 15 |
Crizotinib improves intracranial metastasis control
|
Brower, Vicki
|
|
2016
|
17 |
5 |
p. e184-
1 p.
|
artikel
|
| 16 |
Dabrafenib in patients with BRAF V600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
|
Planchard, David
|
|
2016
|
17 |
5 |
p. 642-650
9 p.
|
artikel
|
| 17 |
Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis
|
Callegaro, Dario
|
|
2016
|
17 |
5 |
p. 671-680
10 p.
|
artikel
|
| 18 |
Dual inhibition of oncogenic targets for B-cell malignancies
|
Richardson, Paul G
|
|
2016
|
17 |
5 |
p. 547-549
3 p.
|
artikel
|
| 19 |
Ethical issues of clinical trials in paediatric oncology from 2003 to 2013: a systematic review
|
Dupont, Jean-Claude K
|
|
2016
|
17 |
5 |
p. e187-e197
nvt p.
|
artikel
|
| 20 |
Impact of Brexit on cancer care and research
|
The Lancet Oncology,
|
|
2016
|
17 |
5 |
p. 539-
1 p.
|
artikel
|
| 21 |
Improved drug access in low and middle-income countries
|
The Lancet Oncology,
|
|
2016
|
17 |
5 |
p. 539-
1 p.
|
artikel
|
| 22 |
Inflammatory breast cancer: a new approach
|
Cristofanilli, Massimo
|
|
2016
|
17 |
5 |
p. 544-546
3 p.
|
artikel
|
| 23 |
Justifying vein resection with pancreatoduodenectomy
|
Crippa, Stefano
|
|
2016
|
17 |
5 |
p. e177-e178
nvt p.
|
artikel
|
| 24 |
Justifying vein resection with pancreatoduodenectomy – Author's reply
|
Barreto, Savio G
|
|
2016
|
17 |
5 |
p. e178-
1 p.
|
artikel
|
| 25 |
Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254
|
Thanarajasingam, Gita
|
|
2016
|
17 |
5 |
p. 663-670
8 p.
|
artikel
|
| 26 |
Low public awareness of link between cancer and alcohol
|
Burki, Talha Khan
|
|
2016
|
17 |
5 |
p. e184-
1 p.
|
artikel
|
| 27 |
Lung cancer CT screening: is annual screening necessary?
|
Field, John K
|
|
2016
|
17 |
5 |
p. 543-544
2 p.
|
artikel
|
| 28 |
Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial
|
Patz Jr, Edward F
|
|
2016
|
17 |
5 |
p. 590-599
10 p.
|
artikel
|
| 29 |
Ma Ma
|
Howe, Rhiannon
|
|
2016
|
17 |
5 |
p. 565-
1 p.
|
artikel
|
| 30 |
Neratinib after trastuzumab in patients with HER2-positive breast cancer
|
Hasegawa, Takahiro
|
|
2016
|
17 |
5 |
p. e176-
1 p.
|
artikel
|
| 31 |
Neratinib after trastuzumab in patients with HER2-positive breast cancer – Author's reply
|
Chan, Arlene
|
|
2016
|
17 |
5 |
p. e176-e177
nvt p.
|
artikel
|
| 32 |
Nominal nomograms and marginal margins: what is the law of the line?
|
Randall, R Lor
|
|
2016
|
17 |
5 |
p. 554-556
3 p.
|
artikel
|
| 33 |
Pazopanib for both GIST and soft-tissue sarcoma
|
Nishida, Toshirou
|
|
2016
|
17 |
5 |
p. 549-550
2 p.
|
artikel
|
| 34 |
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial
|
Mir, Olivier
|
|
2016
|
17 |
5 |
p. 632-641
10 p.
|
artikel
|
| 35 |
Ponatinib for chronic myeloid leukaemia: future perspectives
|
Fava, Carmen
|
|
2016
|
17 |
5 |
p. 546-547
2 p.
|
artikel
|
| 36 |
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
|
Lipton, Jeffrey H
|
|
2016
|
17 |
5 |
p. 612-621
10 p.
|
artikel
|
| 37 |
Potential treatment for a subtype of glioblastoma tumours
|
Granovetter, Michael
|
|
2016
|
17 |
5 |
p. e182-
1 p.
|
artikel
|
| 38 |
Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort
|
Chow, Eric J
|
|
2016
|
17 |
5 |
p. 567-576
10 p.
|
artikel
|
| 39 |
Prostate cancer urine assay could spare biopsies
|
Carlson, Robert H
|
|
2016
|
17 |
5 |
p. e185-
1 p.
|
artikel
|
| 40 |
Proton beam therapy for medulloblastoma
|
Jones, Bleddyn
|
|
2016
|
17 |
5 |
p. e173-
1 p.
|
artikel
|
| 41 |
Proton beam therapy for medulloblastoma
|
English, Martin
|
|
2016
|
17 |
5 |
p. e174-
1 p.
|
artikel
|
| 42 |
Proton beam therapy for medulloblastoma
|
Ramaswamy, Vijay
|
|
2016
|
17 |
5 |
p. e173-e174
nvt p.
|
artikel
|
| 43 |
Proton beam therapy for medulloblastoma – Author's reply
|
Yock, Torunn I
|
|
2016
|
17 |
5 |
p. e174-e175
nvt p.
|
artikel
|
| 44 |
Quicksand
|
Burki, Talha Khan
|
|
2016
|
17 |
5 |
p. 564-
1 p.
|
artikel
|
| 45 |
Radiotherapy challenges in Uganda
|
Burki, Talha Khan
|
|
2016
|
17 |
5 |
p. e185-
1 p.
|
artikel
|
| 46 |
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
|
Younes, Anas
|
|
2016
|
17 |
5 |
p. 622-631
10 p.
|
artikel
|
| 47 |
Sugar tax in the UK
|
Burki, Talha Khan
|
|
2016
|
17 |
5 |
p. e182-
1 p.
|
artikel
|
| 48 |
Sulindac plus erlotinib for familial adenomatous polyposis
|
Baker, Holly
|
|
2016
|
17 |
5 |
p. e183-
1 p.
|
artikel
|
| 49 |
Targeted therapy in BRAF-mutated lung adenocarcinoma
|
Laurie, Scott A
|
|
2016
|
17 |
5 |
p. 550-551
2 p.
|
artikel
|
| 50 |
Targeting macrophages to treat pancreatic cancer
|
Philip, Philip A
|
|
2016
|
17 |
5 |
p. 552-553
2 p.
|
artikel
|
| 51 |
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
|
Nywening, Timothy M
|
|
2016
|
17 |
5 |
p. 651-662
12 p.
|
artikel
|
| 52 |
The EU: what's best for UK cancer research and patients?
|
Selby, Peter
|
|
2016
|
17 |
5 |
p. 556-557
2 p.
|
artikel
|
| 53 |
The metamorphosis of cancer care
|
Swain, Kelley
|
|
2016
|
17 |
5 |
p. 563-
1 p.
|
artikel
|
| 54 |
The US Cancer Moonshot initiative
|
Aelion, C Marjorie
|
|
2016
|
17 |
5 |
p. e178-e180
nvt p.
|
artikel
|
| 55 |
Time for better presentation and analysis of adverse events
|
Mendoza, Tito
|
|
2016
|
17 |
5 |
p. 553-554
2 p.
|
artikel
|
| 56 |
Tyrosine kinase inhibitors as first-line treatment in NSCLC
|
Maemondo, Makoto
|
|
2016
|
17 |
5 |
p. 541-543
3 p.
|
artikel
|
| 57 |
Under-reporting of harm in clinical trials
|
Seruga, Bostjan
|
|
2016
|
17 |
5 |
p. e209-e219
nvt p.
|
artikel
|
| 58 |
Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapy
|
Lee, Jae Y
|
|
2016
|
17 |
5 |
p. e198-e208
nvt p.
|
artikel
|
Tijdschrift beschrijving